Scholarlink

Goal <p>To evaluate the association between glucagon-like peptide-1 receptor agonists (GLP-1 RA) therapy and pancreatic, gastrointestinal, and mortality outcomes in chronic pancreatitis (CP) using the TriNetX US Collaborative Network.</p> Background <p>CP patients face heightened risks of pancreatic insufficiency, cancer, and mortality. There are concerns regarding GLP-1 RA use and adverse pancreatic outcomes.</p> Methods <p>In this retrospective cohort study, adults (age ≥ 18 years) with CP (ICD-10-CM K86.0 or K86.1) were stratified into Cohort 1 (CP + GLP-1 RA, <i>n</i> = 10,978) and Cohort 2 (CP without GLP-1 RA, <i>n</i> = 245,024. After propensity score matching on age, sex, race, and comorbidities, 10,625 patients remained in each cohort. Primary and secondary outcomes were assessed over 3 years via risk analyses and Kaplan-Meier survival analyses.</p> Results <p>GLP-1 RA users had significantly lower incidence of exocrine insufficiency (3.1% vs. 6.3%; RR 0.491, 95%CI 0.429–0.562, <i>p</i> &lt; 0.001), endocrine insufficiency (6.0% vs. 8.2%; RR 0.742, 95%CI 0.664–0.829, <i>p</i> &lt; 0.001), recurrent acute pancreatitis (5.8% vs. 10.5%; RR 0.554, 95%CI 0.487–0.631, <i>p</i> &lt; 0.001), pancreatic cancer (2.0% vs. 3.9%; RR 0.498, 95%CI 0.421–0.590, <i>p</i> &lt; 0.001), ED visits (17.4% vs. 22.4%; RR 0.778, <i>p</i> &lt; 0.001), hospitalizations (18.0% vs. 26.3%; RR 0.684, <i>p</i> &lt; 0.001), and gastroparesis (2.3% vs. 3.0%; RR 0.771, <i>p</i> = 0.003). Critically, all-cause mortality was 6.9% in GLP-1 RA users versus 16.4% in non-users (RR 0.423, 95%CI 0.390–0.459, <i>p</i> &lt; 0.001), with 3-year survival of 88.6% versus 79.1%.</p> Conclusions <p>GLP-1 RA use was associated with substantially lower risks of pancreatic and gastrointestinal outcomes, along with improved overall survival, providing observational evidence supporting safety signals.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Glucagon-like peptide-1 receptor agonists and pancreatic outcomes in chronic pancreatitis: a real-world cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月16日

查看全文
  • Arkadeep Dhali,
  • Rick Maity,
  • Fayaz Khan,
  • Jyotirmoy Biswas,
  • Abdul Rafae Faisal

摘要

Goal

To evaluate the association between glucagon-like peptide-1 receptor agonists (GLP-1 RA) therapy and pancreatic, gastrointestinal, and mortality outcomes in chronic pancreatitis (CP) using the TriNetX US Collaborative Network.

Background

CP patients face heightened risks of pancreatic insufficiency, cancer, and mortality. There are concerns regarding GLP-1 RA use and adverse pancreatic outcomes.

Methods

In this retrospective cohort study, adults (age ≥ 18 years) with CP (ICD-10-CM K86.0 or K86.1) were stratified into Cohort 1 (CP + GLP-1 RA, n = 10,978) and Cohort 2 (CP without GLP-1 RA, n = 245,024. After propensity score matching on age, sex, race, and comorbidities, 10,625 patients remained in each cohort. Primary and secondary outcomes were assessed over 3 years via risk analyses and Kaplan-Meier survival analyses.

Results

GLP-1 RA users had significantly lower incidence of exocrine insufficiency (3.1% vs. 6.3%; RR 0.491, 95%CI 0.429–0.562, p < 0.001), endocrine insufficiency (6.0% vs. 8.2%; RR 0.742, 95%CI 0.664–0.829, p < 0.001), recurrent acute pancreatitis (5.8% vs. 10.5%; RR 0.554, 95%CI 0.487–0.631, p < 0.001), pancreatic cancer (2.0% vs. 3.9%; RR 0.498, 95%CI 0.421–0.590, p < 0.001), ED visits (17.4% vs. 22.4%; RR 0.778, p < 0.001), hospitalizations (18.0% vs. 26.3%; RR 0.684, p < 0.001), and gastroparesis (2.3% vs. 3.0%; RR 0.771, p = 0.003). Critically, all-cause mortality was 6.9% in GLP-1 RA users versus 16.4% in non-users (RR 0.423, 95%CI 0.390–0.459, p < 0.001), with 3-year survival of 88.6% versus 79.1%.

Conclusions

GLP-1 RA use was associated with substantially lower risks of pancreatic and gastrointestinal outcomes, along with improved overall survival, providing observational evidence supporting safety signals.